It has been determined that different amino acid substitutions in oncogenic KRAS differently modulate EZH2 expression in lung adenocarcinoma showing that KRASG12C is associated with higher EZH2 expression [52]. This evidence concerns the gene EZH2 and lung adenocarcinoma.